Secondary Logo

Journal Logo

Abstracts: ASAIO Bioengineering/tissue Engineering Abstracts


Alston, Steven M1; Solen, Kenneth A1; Mohammad, Fazal2; Sukavaneshvar, Sivaprasad2

Author Information
  • Free

Concentrated fibrinogen is needed for fibrin sealants to stop excessive bleeding during and after surgery. Commercial concentrates are expensive and inconvenient, and current methods to concentrate autologous fibrinogen are time consuming or result in low fibrinogen concentrations. A novel method to quickly and easily collect and concentrate autologous fibrinogen is presented, along with quantitative characterization. Fibrinogen was rapidly (10–15 minutes) precipitated and separated from pooled human plasma and then concentrated to 5X, 10X, 15X, and 20X. Sealant made from each concentration (n=8) was evaluated as follows: Sealant tensile strength was assessed by forming clots in a dogbone-shaped mold and testing the clot in a tensile-testing machine. Sealant adhesive strength was assessed by deploying sealant between two overlapping strips of bovine aorta and testing the glued strips in a tensile-testing machine. Sealant hemostatic efficacy was evaluated by deploying sealant on controlled incisions in the kidneys of rats and quantifying blood loss for a fixed time (compared with a sham sealant used on the opposing kidney). All results exhibited good reproducibility (typical standard deviations < 10% of mean). Both tensile and adhesive strengths increased with sealant fibrinogen concentration to values that compare favorably with commercial sealant. In-vivo hemostatic efficacy was demonstrated with all fibrinogen concentrations, producing significantly reduced blood loss (90% reduction was typical) compared with controls (p<0.05).

Copyright © 2005 by the American Society for Artificial Internal Organs